期刊
JOURNAL OF CLINICAL ANESTHESIA
卷 39, 期 -, 页码 129-138出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jclinane.2017.03.038
关键词
Magnesium sulfate; Anesthetics dose
Background: Magnesium sulfate displays numerous characteristics that make it a useful drug in anesthesiology (N-methyl-D-aspartate receptor antagonist, vasodilator, antiarrhythmic, inhibitor of catecholamine release and of acetylcholine in the terminal motor plate). The perioperative use of this drug as an adjuvant capable of decreasing the required dose of anesthetics, has been proposed. Objectives: To assess the influence of intravenous magnesium sulfate administration during general anesthesia on the overall dose of required anesthetics. Design: A systematic review of controlled randomized trials and meta -analysis. Data sources: An electronic bibliography search in MEDLINE and in the Cochrane Database of Controlled trials (CENTRAL) up to 2015. Study eligibility criteria, participants and interventions: Randomized, double-blind trials relating to general anesthesia in elective surgery using intravenous magnesium sulfate that provide information about the anesthetic requirements in ASA I and II patients. Results: 20 clinical trials were selected for the qualitative analysis and 19 for the quantitative one. The use of perioperative intravenous magnesium sulfate reduces the requirement of the anesthetic, propofol during induction (-28.52 mg; CI 95% 35.22-1.82; p <0.001) and maintenance (-213.56 mg; CI 95% -322.93, -104.18; p < 0.001) of anesthesia. Additionally, magnesium sulfate reduces the requirement of neuromuscular nondespolarizing blocking agents (-2.99 mg; CI 95% -44.47, 1.99; p < 0.001) and the intraoperative consumption of fentanile( -53.57 mcg; CI 95% -75.01, -32.12; p <0.001). Conclusions: We conclude that perioperative magnesium sulfate acts as a coadjuvant drug capable of reducing anesthetic requirements. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据